Navigation Links
Dainippon Sumitomo Pharma and SanBio Collaborate on Cell Therapy for Stroke Recovery
Date:10/4/2010

MOUNTAIN VIEW, Calif., Oct. 4 /PRNewswire/ -- Dainippon Sumitomo Pharma Co., Ltd. (DSP) and SanBio, Inc. (SanBio) today announced that they have entered into an option agreement to co-develop a new cell therapy for stroke recovery.

Under the agreement, DSP has received an option for exclusive U.S. and Canadian marketing rights to SB623.  SB623 is a promising cell therapy drug candidate being developed by SanBio for disabilities caused by stroke for which there are currently no effective therapies.  SB623 is an allogeneic cell product, derived from bone marrow stromal cells isolated from healthy donors.  Unlike autologous cell therapy, which requires individualized cell preparation, SB623 production can be scaled, enabling a more cost effective therapy for stroke patients. In preclinical studies to date, SB623 has dramatically improved function in animal models of stroke disability with no significant adverse effects.  The US FDA has recently permitted the initiation of human clinical trial of this innovative cell therapy.

"We expect to exercise this option based on results of a Phase I/IIa trial, already in preparation, and, if these results are favorable, intend to secure exclusive marketing rights to SB623 in the U.S. and Canada," said Masayo Tada, President and Chief Executive Officer of DSP.  "This therapy is an exciting, innovative approach to a profound unmet need for millions of patients. We believe SB623 can contribute to improved health and well being for people throughout the U.S. and Canada."

"Also, for DSP, this therapy is an excellent strategic fit. Our group has been developing business in North America through our subsidiary Sepracor Inc., soon to be called Sunovion Pharmaceuticals Inc.  The addition of this product should enhance our leadership position in the central nervous system (CNS) field, one of our highest priority therapeutic areas."

Keita Mori, co-CEO of SanBio, said, "DSP is an
'/>"/>

SOURCE SanBio, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. OncoGenex Pharmaceuticals to Present at the 9th Annual BIO Investor Forum
2. PDL BioPharma Completes October 1 Special Dividend Payment
3. Inaugural Pharma Exchange Conference Produced by Informex to Draw Together Milwaukee, Wisconsin Chemical Industry
4. Access Pharmaceuticals Furthers Progress on Its Cobalamin-mediated Targeted Drug Delivery Platform for siRNA
5. Syndax Pharmaceuticals to Present at BIO Investor Forum
6. ISTA Pharmaceuticals Highlights Clinical Data from REMURAâ„¢ Phase 2 Study Presented at the 6th International Conference on the Tear Film & Ocular Surface
7. Jiangbo Pharmaceuticals Announces Conference Call to Discuss Results for Fourth Quarter Fiscal 2010
8. Reportlinker Adds Shire plc: PharmaVitae Profile
9. Kevin Kruse Named Executive Director of the Society of Pharmaceutical and Biotech Trainers
10. Genesis Biopharma Announces $700K Private Financing
11. Signal Genetics Announces Partnership with Array BioPharma to Advance a Multiple Myeloma Program Backed by Companion Diagnostics
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... 2, 2014  Technology Applications International Corporation (the "Company" ... subsidiary Renuell Int,l, Inc. has signed an additional exclusive ... ("NASA") at the Johnson Space Center in ... tapplic.com/houstonphotos/ Charles J. ... to announce our latest, exclusive agreement with NASA. In ...
(Date:9/2/2014)... 2014 /PRNewswire/ - Oncothyreon Inc. (Nasdaq: ONTY ) announced ... Executive Officer, will present at the Rodman & Renshaw 16 ... York on Tuesday, Sept. 9, 2014 at 2:05 ... of the presentation will be accessible by visiting the Oncothyreon ... About Oncothyreon Oncothyreon is ...
(Date:9/2/2014)... Massachusetts , September 2, 2014 ... to BioData,s research and lab management services  ... management service, is pleased to announce the appointment of ... Culot most recently served as VP Marketing and Business ... life science research and clinical applications. Previously, ...
(Date:8/31/2014)... 31, 2014 Wockhardt Limited today announces a ... Anti-Infective research when two of its drugs, WCK 771 ... Product (QIDP) status from U.S. Food & Drug Administration ... against pathogens which have a high degree of unmet ... for Disease Control (a top U.S. government health and ...
Breaking Biology Technology:Technology Applications International Corporation Subsidiary Enters Into Additional Exclusive Agreement with NASA at a Signing Ceremony at the Johnson Space Center In Houston, Texas 2Technology Applications International Corporation Subsidiary Enters Into Additional Exclusive Agreement with NASA at a Signing Ceremony at the Johnson Space Center In Houston, Texas 3Louis Culot Appointed as BioData's CEO 2U.S. FDA Grants QIDP Status for Wockhardt Anti-Infective Drug Discovery Program 2U.S. FDA Grants QIDP Status for Wockhardt Anti-Infective Drug Discovery Program 3
... /PRNewswire-FirstCall/ - Angiotech Pharmaceuticals,Inc. ("Angiotech") (NASDAQ: ... and medical device company, today announced that ... (the "Tender Offer"),for its outstanding Senior Floating ... "First Priority Notes"), and its outstanding 7.75% ...
... breadth of experience and business expertise, SCOTTSDALE, ... technology company that markets the Provant(R) Wound Therapy,System, ... its Board of,Directors. The two new directors are ... and Charles "Chuck" S. Lunden, a principal with,Bederson ...
... ... the job done, NEWARK, N.J., Aug. 22 BioNeutral announced ... its,Ogiene(TM) FE technology to bring 10,000 mobile homes into full compliance,so ... in need,of biohazard-free housing., Dr. Andy Kielbania, Chief Scientist at ...
Cached Biology Technology:Angiotech Announces Extension of the Expiration Date of its Tender Offer for Senior Floating Rate Notes Due 2013 and 7.75% Senior Subordinated Notes Due 2014 2Angiotech Announces Extension of the Expiration Date of its Tender Offer for Senior Floating Rate Notes Due 2013 and 7.75% Senior Subordinated Notes Due 2014 3Angiotech Announces Extension of the Expiration Date of its Tender Offer for Senior Floating Rate Notes Due 2013 and 7.75% Senior Subordinated Notes Due 2014 4Angiotech Announces Extension of the Expiration Date of its Tender Offer for Senior Floating Rate Notes Due 2013 and 7.75% Senior Subordinated Notes Due 2014 5Regenesis Biomedical Announces Additions to Board of Directors 2BioNeutral Signs Agreement With a Non-profit for Long-Term Removal of Formaldehyde to Save 10,000 Mobile Homes in Louisiana 2
(Date:9/2/2014)... is enough to prevent Type 2 diabetes, don,t get your ... of The FASEB Journal , suggests that ... diabetes. This study compared genetically identical twins-one heavier and one ... metabolites, including those related to Type 2 diabetes, were found ... suggest that the onset of this type of diabetes is ...
(Date:9/2/2014)... published in the September issue of The ... novel strategy to diagnose the leading cause of ... damage has occurred. This advance involves quantifying the ... endothelium of retinal vessels. Using new probes developed ... early molecular development of diabetic retinopathy. , "My ...
(Date:9/2/2014)... as perching birds, that migrate by night tend to ... to reach their destinations. This seasonal difference in flight ... short migratory flights, says researcher Cecilia Nilsson of Lund ... and Sociobiology . , Nilsson, in a group ... to measure over three years the speed by which ...
Breaking Biology News(10 mins):What you eat and not just the number of calories, is a significant factor in diabetes risk 2Molecular probes permit doctors to detect diabetic retinopathy before vision fails 2Migrating birds sprint in spring, but take things easy in autumn 2
... new study finds that Caribbean seaweeds are far better competitors ... this triumph is bad news for Caribbean coral reefs. ... the living corals that build reefs and contribute startling white ... environment but in fact a battle is constantly waged between ...
... Obama has made cyber security an integral issue when ... ensure that the U.S. remains on the cutting edge, ... will convene a gathering of the nation,s top minds ... issues affecting the economy and United States, national security. ...
... Smith, Ph.D., Wellcome Trust Principal Research Fellow and ... Fellow of Emmanuel College, Cambridge, has been bestowed ... Award, recognizing exemplary leadership in the international microbiological ... University of Virginia, says Smith is "internationally recognized ...
Cached Biology News:Jim Demitrieus, CEO of EyeLock, Invited to White House Cyber Security Event 2Jim Demitrieus, CEO of EyeLock, Invited to White House Cyber Security Event 3The American Society for Microbiology honors Geoffrey L. Smith 2
Caliper offers a wide array of standard LabChip products designed to be used in combination with our AMS 90 and LabChip 3000 microfluidic platforms....
Caliper offers a wide array of standard LabChip products designed to be used in combination with our AMS 90 and LabChip 3000 microfluidic platforms....
...
...
Biology Products: